Magnetic cell sorting of CD138 + plasma cells and CD31 + endothelial cells
Approval for this study involving human subjects was obtained from the Chinese University of Hong Kong institutional review board. Informed consent was provided according to the Declaration of Helsinki. Bone marrow mononuclear cells from MM patients or healthy donors were separated using Ficoll-Hypaque density gradient centrifugation (Amersham Biosciences, Piscataway, NJ, USA). Immunomagnetic separation of plasma cells or endothelial cells was performed using CD138 or CD31 microbeads and miniMACS (MiltenyiBiotec, Auburn, CA, USA) according to manufacturer's protocol. The purities of plasma cells and endothelial cells obtained were >95%, as confirmed by flow cytometry.
Cell growth and proliferation assay
MM cell lines were seeded in 96-well plates at a density of 1x10 4 cells per well and treated with PF4. At the end of incubation, cell growth was determined by WST-1 (Roche, Germany) assay and cell numbers were determined by the trypan blue dye exclusion method according to the manufacturer's protocol.
Apoptosis assay
Untreated or PF4-treated cells were stained with annexin Vphycoerythrin and 7-amino-actinomycin D (7-AAD) according to the manufacturer's directions (Apoptosis Detection Kit; BD Biosciences) and the percentage of apoptotic cells was determined by flow cytometry (BD Biosciences). After cells had been treated with phosphate-buffered saline (PBS) or 8 mM PF4, apoptosis was also determined by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay (Roche), caspase-3 activity assay (Chemicon, Temecula, CA, USA) and immunoblotting with cleaved PARP according to the manufacturers' instructions.
In vitro tube formation assay
Unpolymerized Matrigel (BD Biosciences) was placed (50 mL/well) in a 96-well microtiter plate (0.32 cm 2 /well) and polymerized for 1 h at 37°C. MM bone marrow endothelial cells (1x10 4 per well) in 100 mL medium in the presence or absence of PF4 were layered onto the Matrigel surface. After 6 h of incubation in a 5% CO2 humidified atmosphere at 37°C, tube formation was observed using a reverted phase-contrast light microscope (Olympus, Japan).
Protein/DNA arrays and electrophoretic mobility shift assay U266 and OPM2 cells were treated with PBS or PF4 for 8 h. Nuclear extracts from cells were prepared with a nuclear extraction kit (Panomics, Santa Clara, CA, USA). Protein/DNA arrays and the electrophoretic mobility shift assay were performed according to the manufacturer's protocol (Panomics).
Luciferase reporter assay
U266 cells were transfected with STAT3-Luc (Stratagene, Santa Clara, CA, USA) and pRL-TK (Promega, Madison, WI, USA). After incubation for 16 h, PBS or PF4 was added and the incubation was continued for 8 h. Cells were then harvested and the activities of firefly and Renilla luciferases in cell lysates were determined with a dual luciferase reporter assay system (Promega). Normalized data were calculated as the quotient of Renilla/firefly luciferase activities. All the experiments were performed in triplicate.
Western blotting
The western blots were performed as previously described. (Abcam, Cambridge, MA, USA), Bcl-2 (1:1000), Bcl-XL (1:1000) (BD Biosciences), and VEGF (1:1000) (Santa Cruz, Biotechnology, Santa Cruz, CA, USA).
RNA extraction and real-time polymerase chain reaction
First-strand cDNA was synthesized from one microgram of total RNA using MuLV reverse transcriptase, random hexamers and RNase inhibitor (Applied Biosystems, Carlsbad, CA, USA). To assess mRNA expression of putative genes, a real-time polymerase chain reaction (PCR) was performed using SYBR Green PCR master-mix according to the manufacturer's protocol (HT7300 system, Applied Biosystems). PCR primer sequences are listed in Online Supplementary Table S1 .
Cell transfections
NCI-H929 cells were transfected with constitutively active STAT3 plasmid (Stat3-C Flag pRc/CMV) kindly provided by Dr. Jim Darnell (Addgene plasmid 8722), 2 or empty vector (pcDNA3.1) using Nucleofector Kit T solution (Lonza, Germany). Stable clones were selected by G418 (Invitrogen). For knockdown of SOCS3, CXCR3B and LRP1, U266 cells were transfected with SOCS3 (Cell Signaling), CXCR3B or LRP1 (Applied Biosystems) and scrambled short-interfering RNA using Nucleofactor Kit C solution.
Subcutanous Matrigel xenograft and severe combined immunodeficient-rab mouse models
Six-to 8-week-old male non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice were housed and monitored in our Animal Research Facility. All experimental procedures and protocols had been approved by the Animal Experimentation Ethics Committee (The Chinese University of Hong Kong). In the subcutaneous Matrigel xenograft model, mice were inoculated subcutaneously with 3x10 7 OPM2 cells in 100 mL of RPMI 1640 medium, together with 100 mL of Matrigel (BD Biosciences). When the tumor was measurable, mice were treated by tail vein injection with PF4 (200 ng) or PBS three times/week. For the severe combined immunodeficiency-rabbit (SCID-rab) mouse model, femora and tibiae from 4-week old New Zealand rabbit bone grafts were subcutaneously implanted into SCID mice, as previously described.
3 Eight weeks after bone implantation, 1x10 6 U266 cells were injected directly into the rabbit bone implant. Mouse sera were monitored serially for the levels of circulating immunoglobulin (hIg) of the M-protein isotype (lambda light chain) by an enzyme-linked immunosorbent assay according to the manufacturer's protocols (Bethyl, Montgomery, TX, USA). Mice were injected via the tail vein with PBS or PF4 (200 ng or 20 ng per mouse three times/week) for 12 consecutive weeks.
Immunohistochemistry
Twelve weeks after treatment with PF4, rabbit bones were fixed and decalcified with 8% formic acid (Sigma-Aldrich, St Louis, MO, USA). The bones were embedded in paraffin for sectioning. Sections were probed with CD138(1:50) (Abcam), CD31(1:30), VEGF (1:100) (DAKO, Denmark), cleaved caspase-3 (1:1600), and STAT3 (1:100) (Cell Signaling). Immunocomplexes were visualized using diaminobenzidinetetrahydrochloride (DAB) substrate (BD Biosciences) and counterstained with hematoxylin.
Statistical analysis
Whether differences observed in PF4-treated versus control cultures were statistically significant was determined using the Student's t-test. Values are represented by the mean ± standard deviation (SD) or standard error of the mean (SEM) of triplicate experiments. A P value <0.05 was considered statistically significant. Statistical significance in animal studies was determined using Student's t-test. Survival of mice was evaluated using Kaplan-Meier analysis.
Online Supplementary Table S1 . Primers used for real-time PCR in this study.
Online Supplementary Figure S1 . Pretreatment with cycloheximide diminished the apoptotic effect of PF4 on MM cells. OPM2 cells were pretreated with cycloheximide (CHX) (2 mg/mL for 2 h), followed by exposure to 4 mM PF4 for 96 h. Apoptosis was measured by flow cytometry using annexin V/7-AAD staining. Results from three experiments are shown (P=0.001). 
